Variation and Trends in Antidepressant Prescribing for Men Undergoing Treatment for Nonmetastatic Prostate Cancer

A Population-based Cohort Study

Rano Matta, Christopher J.D. Wallis, Mitchell G. Goldenberg, Amanda E. Hird, Zachary W A Klaassen, Girish Kulkarni, Ronald T. Kodama, Sender Herschorn, Robert K. Nam

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Psychological distress is prevalent among men with prostate cancer (PCa). However, the variation in antidepressant use among individuals throughout the survivorship period is unknown. We sought to examine the variation and trends in receipt of antidepressants after PCa treatment, among patients with nonmetastatic PCa. Using population-based linked administrative data, we identified men ≥66 yr old who underwent surgery (n = 4952), radiotherapy (n = 4994), or surveillance (n = 2136), and these men were matched to general population controls (n = 57 127). One year prior to PCa treatment, 7.7% of men received an antidepressant prescription, which increased to 10.5% in the year after treatment. In difference-in-differences analysis, adjusted for demographic and health characteristics, men had increased odds of antidepressant receipt up to 5 yr after surgery (odds ratio [OR] 1.49; 95% confidence interval [CI] 1.35–1.64; p ≤ 0.0001) or radiotherapy (OR 1.33; 95% CI 1.21–1.47; p ≤ 0.0001). Men did not have an increased risk of antidepressant receipt up to 5 yr after surveillance (OR 1.15; 95% CI 0.94–1.41; p = 0.16). Limitations include the potential for selection bias and misclassification due to the retrospective design of the study and the use of administrative databases. Thus, men with nonmetastatic PCa who initially receive surgery or radiotherapy, but not those who initially undergo surveillance, have an increased risk of antidepressant receipt after treatment. Patient summary: In this report, we examined antidepressant prescription for men after treatment of nonmetastatic prostate cancer across the entire population of men ≥66 yr in Ontario, Canada, from 2002 to 2009. For men diagnosed with nonmetastatic prostate cancer, the risk of antidepressant receipt at 5 yr after treatment was significantly increased after surgery or radiotherapy, but not after surveillance. Providers and patients should consider the psychological effects of prostate cancer treatment during the survivorship period. Patients treated for nonmetastatic prostate cancer with surgery or radiation have an increased risk of receiving antidepressant prescriptions for at least 5 yr, whereas patients undergoing surveillance do not. Thus, psychological support after treatment is an important part of prostate cancer care.

Original languageEnglish (US)
Pages (from-to)3-7
Number of pages5
JournalEuropean urology
Volume75
Issue number1
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Fingerprint

Antidepressive Agents
Prostatic Neoplasms
Cohort Studies
Population
Radiotherapy
Prescriptions
Therapeutics
Odds Ratio
Confidence Intervals
Psychology
Survival Rate
Men's Health
Population Control
Selection Bias
Ontario
Canada
Retrospective Studies
Demography
Databases
Radiation

Keywords

  • Antidepressive agents
  • Prostatectomy
  • Prostatic neoplasms
  • Radiotherapy
  • Survivorship

ASJC Scopus subject areas

  • Urology

Cite this

Variation and Trends in Antidepressant Prescribing for Men Undergoing Treatment for Nonmetastatic Prostate Cancer : A Population-based Cohort Study. / Matta, Rano; Wallis, Christopher J.D.; Goldenberg, Mitchell G.; Hird, Amanda E.; Klaassen, Zachary W A; Kulkarni, Girish; Kodama, Ronald T.; Herschorn, Sender; Nam, Robert K.

In: European urology, Vol. 75, No. 1, 01.01.2019, p. 3-7.

Research output: Contribution to journalArticle

Matta, Rano ; Wallis, Christopher J.D. ; Goldenberg, Mitchell G. ; Hird, Amanda E. ; Klaassen, Zachary W A ; Kulkarni, Girish ; Kodama, Ronald T. ; Herschorn, Sender ; Nam, Robert K. / Variation and Trends in Antidepressant Prescribing for Men Undergoing Treatment for Nonmetastatic Prostate Cancer : A Population-based Cohort Study. In: European urology. 2019 ; Vol. 75, No. 1. pp. 3-7.
@article{6dd68bebf0e243969e6de5ce2ad27327,
title = "Variation and Trends in Antidepressant Prescribing for Men Undergoing Treatment for Nonmetastatic Prostate Cancer: A Population-based Cohort Study",
abstract = "Psychological distress is prevalent among men with prostate cancer (PCa). However, the variation in antidepressant use among individuals throughout the survivorship period is unknown. We sought to examine the variation and trends in receipt of antidepressants after PCa treatment, among patients with nonmetastatic PCa. Using population-based linked administrative data, we identified men ≥66 yr old who underwent surgery (n = 4952), radiotherapy (n = 4994), or surveillance (n = 2136), and these men were matched to general population controls (n = 57 127). One year prior to PCa treatment, 7.7{\%} of men received an antidepressant prescription, which increased to 10.5{\%} in the year after treatment. In difference-in-differences analysis, adjusted for demographic and health characteristics, men had increased odds of antidepressant receipt up to 5 yr after surgery (odds ratio [OR] 1.49; 95{\%} confidence interval [CI] 1.35–1.64; p ≤ 0.0001) or radiotherapy (OR 1.33; 95{\%} CI 1.21–1.47; p ≤ 0.0001). Men did not have an increased risk of antidepressant receipt up to 5 yr after surveillance (OR 1.15; 95{\%} CI 0.94–1.41; p = 0.16). Limitations include the potential for selection bias and misclassification due to the retrospective design of the study and the use of administrative databases. Thus, men with nonmetastatic PCa who initially receive surgery or radiotherapy, but not those who initially undergo surveillance, have an increased risk of antidepressant receipt after treatment. Patient summary: In this report, we examined antidepressant prescription for men after treatment of nonmetastatic prostate cancer across the entire population of men ≥66 yr in Ontario, Canada, from 2002 to 2009. For men diagnosed with nonmetastatic prostate cancer, the risk of antidepressant receipt at 5 yr after treatment was significantly increased after surgery or radiotherapy, but not after surveillance. Providers and patients should consider the psychological effects of prostate cancer treatment during the survivorship period. Patients treated for nonmetastatic prostate cancer with surgery or radiation have an increased risk of receiving antidepressant prescriptions for at least 5 yr, whereas patients undergoing surveillance do not. Thus, psychological support after treatment is an important part of prostate cancer care.",
keywords = "Antidepressive agents, Prostatectomy, Prostatic neoplasms, Radiotherapy, Survivorship",
author = "Rano Matta and Wallis, {Christopher J.D.} and Goldenberg, {Mitchell G.} and Hird, {Amanda E.} and Klaassen, {Zachary W A} and Girish Kulkarni and Kodama, {Ronald T.} and Sender Herschorn and Nam, {Robert K.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.eururo.2018.08.035",
language = "English (US)",
volume = "75",
pages = "3--7",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Variation and Trends in Antidepressant Prescribing for Men Undergoing Treatment for Nonmetastatic Prostate Cancer

T2 - A Population-based Cohort Study

AU - Matta, Rano

AU - Wallis, Christopher J.D.

AU - Goldenberg, Mitchell G.

AU - Hird, Amanda E.

AU - Klaassen, Zachary W A

AU - Kulkarni, Girish

AU - Kodama, Ronald T.

AU - Herschorn, Sender

AU - Nam, Robert K.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Psychological distress is prevalent among men with prostate cancer (PCa). However, the variation in antidepressant use among individuals throughout the survivorship period is unknown. We sought to examine the variation and trends in receipt of antidepressants after PCa treatment, among patients with nonmetastatic PCa. Using population-based linked administrative data, we identified men ≥66 yr old who underwent surgery (n = 4952), radiotherapy (n = 4994), or surveillance (n = 2136), and these men were matched to general population controls (n = 57 127). One year prior to PCa treatment, 7.7% of men received an antidepressant prescription, which increased to 10.5% in the year after treatment. In difference-in-differences analysis, adjusted for demographic and health characteristics, men had increased odds of antidepressant receipt up to 5 yr after surgery (odds ratio [OR] 1.49; 95% confidence interval [CI] 1.35–1.64; p ≤ 0.0001) or radiotherapy (OR 1.33; 95% CI 1.21–1.47; p ≤ 0.0001). Men did not have an increased risk of antidepressant receipt up to 5 yr after surveillance (OR 1.15; 95% CI 0.94–1.41; p = 0.16). Limitations include the potential for selection bias and misclassification due to the retrospective design of the study and the use of administrative databases. Thus, men with nonmetastatic PCa who initially receive surgery or radiotherapy, but not those who initially undergo surveillance, have an increased risk of antidepressant receipt after treatment. Patient summary: In this report, we examined antidepressant prescription for men after treatment of nonmetastatic prostate cancer across the entire population of men ≥66 yr in Ontario, Canada, from 2002 to 2009. For men diagnosed with nonmetastatic prostate cancer, the risk of antidepressant receipt at 5 yr after treatment was significantly increased after surgery or radiotherapy, but not after surveillance. Providers and patients should consider the psychological effects of prostate cancer treatment during the survivorship period. Patients treated for nonmetastatic prostate cancer with surgery or radiation have an increased risk of receiving antidepressant prescriptions for at least 5 yr, whereas patients undergoing surveillance do not. Thus, psychological support after treatment is an important part of prostate cancer care.

AB - Psychological distress is prevalent among men with prostate cancer (PCa). However, the variation in antidepressant use among individuals throughout the survivorship period is unknown. We sought to examine the variation and trends in receipt of antidepressants after PCa treatment, among patients with nonmetastatic PCa. Using population-based linked administrative data, we identified men ≥66 yr old who underwent surgery (n = 4952), radiotherapy (n = 4994), or surveillance (n = 2136), and these men were matched to general population controls (n = 57 127). One year prior to PCa treatment, 7.7% of men received an antidepressant prescription, which increased to 10.5% in the year after treatment. In difference-in-differences analysis, adjusted for demographic and health characteristics, men had increased odds of antidepressant receipt up to 5 yr after surgery (odds ratio [OR] 1.49; 95% confidence interval [CI] 1.35–1.64; p ≤ 0.0001) or radiotherapy (OR 1.33; 95% CI 1.21–1.47; p ≤ 0.0001). Men did not have an increased risk of antidepressant receipt up to 5 yr after surveillance (OR 1.15; 95% CI 0.94–1.41; p = 0.16). Limitations include the potential for selection bias and misclassification due to the retrospective design of the study and the use of administrative databases. Thus, men with nonmetastatic PCa who initially receive surgery or radiotherapy, but not those who initially undergo surveillance, have an increased risk of antidepressant receipt after treatment. Patient summary: In this report, we examined antidepressant prescription for men after treatment of nonmetastatic prostate cancer across the entire population of men ≥66 yr in Ontario, Canada, from 2002 to 2009. For men diagnosed with nonmetastatic prostate cancer, the risk of antidepressant receipt at 5 yr after treatment was significantly increased after surgery or radiotherapy, but not after surveillance. Providers and patients should consider the psychological effects of prostate cancer treatment during the survivorship period. Patients treated for nonmetastatic prostate cancer with surgery or radiation have an increased risk of receiving antidepressant prescriptions for at least 5 yr, whereas patients undergoing surveillance do not. Thus, psychological support after treatment is an important part of prostate cancer care.

KW - Antidepressive agents

KW - Prostatectomy

KW - Prostatic neoplasms

KW - Radiotherapy

KW - Survivorship

UR - http://www.scopus.com/inward/record.url?scp=85053732936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053732936&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2018.08.035

DO - 10.1016/j.eururo.2018.08.035

M3 - Article

VL - 75

SP - 3

EP - 7

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 1

ER -